Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims

Translational Stroke Research

Volumn 2, Issue 2, 2011, Pages 129-135

  Lapchak, Paul A ^a  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CURCUMIN; DISUFENTON SODIUM; INDUCIBLE NITRIC OXIDE SYNTHASE; MINOCYCLINE; NEUROPROTECTIVE AGENT; NORPHENAZONE; PLASMINOGEN ACTIVATOR; TPA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LIPID OXIDATION; NERVE CELL DEGENERATION; NEUROPROTECTION; PLEIOTROPY; PRIORITY JOURNAL;

EID: 79955718269     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-011-0074-4     Document Type: Editorial

References (97)

1. NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995; 333(24): 1581-7.
2. Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke. 2000; 31(5): 1062-8.
3. Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke. 1999; 30(12): 2513-6.
4. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40(12): e647-56.
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317-29.
6. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). Jama. 1995; 274(13): 1017-25.
7. Steiner T, Bluhmki E, Kaste M, Toni D, Trouillas P, von Kummer R, et al. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. Cerebrovasc Dis. 1998; 8(4): 198-203.
8. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007; 357(6): 562-71.
9. Ingall T. Stroke-incidence, mortality, morbidity and risk. J Insur Med. 2004; 36(2): 143-52.
10. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119(3): 480-6.
11. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121(7): 948-54.
12. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121(7): e46-e215.
13. AHA. International Cardiovascular Disease Statistics http://www. americanheart. org/downloadable/heart/1177593979236FS06INTL07. pdf. Accessed March 20, 2011.
14. Caro JJ, Huybrechts KF. Stroke Treatment Economic Model (STEM): predicting long-term costs from functional status. Stroke. 1999; 30: 2574-9.
15. Laffel GL, Braunwald E. Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction (2). N Engl J Med. 1984; 311(12): 770-6.
16. Laffel GL, Braunwald E. Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction (1). N Engl J Med. 1984; 311(11): 710-7.
17. Schmutzler R, Heckner F, Kortge P, van der Loo J, Pezold A, Poliwoda H, et al. Thrombolytic therapy of recent myocardial infarction. I. Introduction, plan of trial, general clinical results. Ger Med Mon. 1966; 11(8): 308-14.
18. Poliwoda H. The thrombolytic therapy of acute myocardial infarction. Angiology. 1966; 17(8): 528-40.
19. Poliwoda H, Diederich KW, Schneider B, Rodenburg R, Heckner F, Kortge P, et al. On the thrombolytic therapy of recent myocardial infarction. 2. Results of electrocardiographic studies. Dtsch Med Wochenschr. 1966; 91(21): 978-84.
20. Schmutzler R, Heckner F, Kortge P, van de Loo J, Poliwoda H, Pezold FA, et al. On thrombolytic therapy of a recent myocardial infarct. I. Introduction, treatment plans, general clinical results. Dtsch Med Wochenschr. 1966; 91(13): 581-7.
21. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010; 11(10): 1753-63.
22. Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs. 2002; 11(11): 1623-32.
23. Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, Hacke W. Thrombolytic therapy for ischemic stroke-a review. Part II-Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging. Crit Care Med. 2001; 29(9): 1819-25.
24. Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, Hacke W. Thrombolytic therapy for ischemic stroke-a review. Part I-Intravenous thrombolysis. Crit Care Med. 2001; 29(9): 1812-8.
25. Verstraete M. Newer thrombolytic agents. Ann Acad Med Singapore. 1999; 28(3): 424-33.
26. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000; 31(8): 1812-6.
27. Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, Hacke W, et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke. 2010; 41(1): e25-33.
28. Alexandrov AV, Schellinger PD, Saqqur M, Barreto A, Demchuk AM, Ribo M. Reperfusion and outcomes in Penumbra vs. systemic tissue plasminogen activator clinical trials. Int J Stroke. 2011; 6(2): 118-22.
29. Molina CA. Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke. 2011; 42(1 Suppl): S16-9.
30. Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010; 41(10): 2254-8.
31. Pandian JD. Re-canalization in acute ischemic stroke: the strategies. Neurol India. 2009; 57(1): 20-7.
32. Soltani A, Clark WM, Hansmann DR. Sonothrombolysis: an emerging modality for the treatment of acute ischemic and hemorrhagic stroke. Transl Stroke Res. 2011; 2(2). doi: 10. 1007/s12975-011-0077-1.
33. Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med. 2010; 5(7): 406-9.
34. Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hickenbottom S, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005; 36(6): 1232-40.
35. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4. 5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009; 40(7): 2438-41.
36. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010; 375(9727): 1695-703.
37. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke. 2009; 40(11): 3591-5.
38. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0. 6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006; 37(7): 1810-5.
39. Otomo E. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003; 15(3): 222-9.
40. Sinha M, Anuradha H, Juyal R, Shukla R, Garg R, Kar A. Edaravone in acute ischemic stroke, an Indian experience. Neurol Asia. 2009; 14: 7-10.
41. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999; 22(9): 391-7.
42. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010; 67(2): 181-98.
43. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999; 79(4): 1431-568.
44. Lapchak PA, De Taboada L. Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5′-triphosphate (ATP) content following embolic strokes in rabbits. Brain Res. 2010; 1306: 100-5.
45. Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med. 1999; 222(3): 236-45.
46. Back T. Pathophysiology of the ischemic penumbra-revision of a concept. Cell Mol Neurobiol. 1998; 18(6): 621-38.
47. Fisher M. The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc Dis. 2004; 17: 1-6.
48. Michel P, Bogousslavsky J. Penumbra is brain: no excuse not to perfuse. Ann Neurol. 2005; 58(5): 661-3.
49. Ferguson KN, Kidwell CS, Starkman S, Saver JL. Hyperacute treatment initiation in neuroprotective agent stroke trials. J Stroke Cerebrovasc Dis. 2004; 13(3): 109-12.
50. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006; 354(6): 588-600.
51. Watanabe T, Tahara M, Todo S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther. 2008; 26(2): 101-14.
52. Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol. 2009; 157(7): 1157-71.
53. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010; 1(2): 96-107. Perspective Review.
54. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007; 205(1): 20-5.
55. Shaller CA, Jacques S, Shelden CH. The pathophysiology of stroke: a review with molecular considerations. Surg Neurol. 1980; 14(6): 433-43.
56. Muir KW. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke. 2002; 33(6): 1545-50.
57. Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007; 12(1): 97-112.
58. Lo EH, Rosenberg GA. The neurovascular unit in health and disease: introduction. Stroke. 2009; 40(3 Suppl): S2-3.
59. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke. 2007; 38(2 Suppl): 748-52.
60. Chen B, Friedman B, Cheng Q, Tsai P, Schim E, Kleinfeld D, et al. Severe blood-brain barrier disruption and surrounding tissue injury. Stroke. 2009; 40(12): e666-74.
61. Sierra C, Coca A, Schiffrin EL. Vascular mechanisms in the pathogenesis of stroke. Curr Hypertens Rep. 2011. doi: 10. 1007/s11906-011-0195-x.
62. Lapchak PA, Schubert D, Maher P. De-risking of Stilbazulenyl nitrone (STAZN), a lipophilic nitrone to treat stroke using a unique panel of in vitro assays. Transl Stroke Res. 2011; 2(2). doi: 10. 1007/s12975-011-0071-7.
63. Becker DA. Diagnostic and therapeutic applications of azulenyl nitrone spin traps. Cell Mol Life Sci. 1999; 56(7-8): 626-33.
64. Becker DA. Azulenyl nitrone spin trapping agents, methods of making and using same. U. S. Patent 6, 291, 702.
65. Becker DA, Ley JJ, Echegoyen L, Alvarado R. Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants. J Am Chem Soc. 2002; 124(17): 4678-84.
66. Belayev L, Becker DA, Alonso OF, Liu Y, Busto R, Ley JJ, et al. Stilbazulenyl nitrone, a novel azulenyl nitrone antioxidant: improved neurological deficit and reduced contusion size after traumatic brain injury in rats. J Neurosurg. 2002; 96(6): 1077-83.
67. Ginsberg MD, Becker DA, Busto R, Belayev A, Zhang Y, Khoutorova L, et al. Stilbazulenyl nitrone, a novel antioxidant, is highly neuroprotective in focal ischemia. Ann Neurol. 2003; 54(3): 330-42.
68. Lapchak PA, Schubert DR, Maher PA. Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem. 2011; 116(1): 122-31.
69. Tan S, Schubert D, Maher P. Oxytosis: A novel form of programmed cell death. Curr Top Med Chem. 2001; 1(6): 497-506.
70. Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. J Neurochem. 2008; 105(4): 1336-45.
71. Lapchak PA, Maher P, Schubert D, Zivin JA. Baicalein, an antioxidant 12/15 lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience. 2007; 150(3): 585-91.
72. Maher P, Salgado KF, Zivin JA, Lapchak PA. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res. 2007; 1173: 117-25.
73. Lapchak PA. KcKim, J. M. CeeTox™ analysis of CNB-001 a novel curcumin-based neurotrophic/neuroprotective lead compound to treat stroke: comparison with NXY-059 and Radicut. Transl Stroke Research. 2011; 2(1): 51-9.
74. Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, et al. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. Stroke. 1999; 30: 2347.
75. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of IV tissue plasmingogen activator in acute stroke: does stroke subtype really matter? Neurology. 2002; 61(1): 71-5.
76. Brown AT, Skinner RD, Flores R, Hennings L, Borrelli MJ, Lowery J, et al. Stroke location and brain function in an embolic rabbit stroke model. J Vasc Interv Radiol. 2010; 21: 903-9.
77. Guluma KZ, Lapchak PA. Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke. Brain Res. 2010; 1354: 206-16.
78. Turner R, Jickling, G, Sharp, F Are underlying assumptions of current animal models of human stroke correct: from STAIRS to high hurdles? Transl Stroke Res. 2011; 2(2). doi: 10. 1007/s12975-011-0067-3.
79. Kawaguchi M, Furuya H, Patel PM. Neuroprotective effects of anesthetic agents. J Anesth. 2005; 19(2): 150-6.
80. Koerner IP, Brambrink AM. Brain protection by anesthetic agents. Curr Opin Anaesthesiol. 2006; 19(5): 481-6.
81. Matchett GA, Allard MW, Martin RD, Zhang JH. Neuroprotective effect of volatile anesthetic agents: molecular mechanisms. Neurol Res. 2009; 31(2): 128-34.
82. Nishikawa K, MacIver MB. Excitatory synaptic transmission mediated by NMDA receptors is more sensitive to isoflurane than are non-NMDA receptor-mediated responses. Anesthesiology. 2000; 92(1): 228-36.
83. d'Esterre C, Tichauer K, Aviv R, Eisert W, Lee T-Y. Dipyridamole treatment prior to stroke onset: examining post-stroke cerebral circulation and outcome in rabbits Transl Stroke Res. 2011; 2(2). doi: 10. 1007/s12975-010-0062-0.
84. Silver JH, Lapchak PA. Continuous Monitoring of Changes in Plasma Nitrite following Cerebral Ischemia in a Rabbit Embolic Stroke Model. Transl Stroke Res. 2011; 2(2). doi: 10. 1007/s12975-011-0073-5.
85. Lapchak PA. A new embolus injection method to evaluate intracerebral hemorrhage in New Zealand white rabbits. Brain Res. 2010; 1349C: 129-36.
86. Brown AT, Skinner RD, Flores R, Hennings L, Borrelli MJ, Lowery J, et al. Stroke location and brain function in an embolic rabbit stroke model. J Vasc Interv Radiol. 2010; 21(6): 903-9.
87. Clinicaltrials. gov: MCI-186. http://clinicaltrials. gov/ct2/show/NCT00821821. Accessed March 19, 2011.
88. Lapchak PA, Zivin JA. The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol. 2009; 215(1): 95-100.
89. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol. 2007; 595: 197-212.
90. Lapchak PA. Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective. Expert Opin Investig Drugs. 2011; 20(1): 13-22.
91. Wang R, Li YB, Li YH, Xu Y, Wu HL, Li XJ. Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res. 2008; 1210: 84-91.
92. Wang R, Li YH, Xu Y, Li YB, Wu HL, Guo H, et al. Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34(1): 147-53.
93. Fagan SC, Cronic LE, Hess DC. Minocycline Development for Acute Ischemic Stroke. Transl Stroke Res. 2011; 2(2). doi: 10. 1007/s12975-011-0072-6.
94. McKim Jr JM. Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb Chem High Throughput Screen. 2010; 13(2): 188-206.
95. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001; 32(7): 1598-606.
96. O'Collins VE, Macleod MR, Cox SF, van Raay L, Aleksoska E, Donnan GA, et al. Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing. J Cereb Blood Flow Metab. 2011; 31: 962-975.
97. Fisher M. New approaches to neuroprotective drug development. Stroke. 2011; 42(1 Suppl): S24-7.